CLINICAL_TRIALS
trial_result
· 2017-01-23
Clinical Trial Update: A Study of the HSP90 Inhibitor AUY922 [Phase 2]
Summary
The Phase 2 trial of the HSP90 inhibitor AUY922 (ganetespib) in lymphoma was terminated, with results posted in January 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-01-23